• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    4/27/23 12:48:47 PM ET
    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ABBV alert in real time by email

    Gainers

    • Evelo Biosciences, Inc. (NASDAQ:EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.
    • ContraFect Corporation (NASDAQ:CFRX) gained 87% to $2.4693. ContraFect said first patient was dosed in the Phase 1b/2 study of exebacase in patients with chronic prosthetic joint infections of the knee.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) jumped 56% to $1.10.
    • TOP Financial Group Limited (NASDAQ:TOP) rose 53.7% to $10.33.
    • U Power Limited (NASDAQ:UCAR) climbed 33.5% to $5.45 after declining around 27% on Wednesday.
    • Atomera Incorporated (NASDAQ:ATOM) shares gained 23.6% to $6.45 after the company posted results for its first quarter. The company announced the execution of a commercial license agreement with STMicroelectronics (ST) that enables the latter to install Atomera's Mears Silicon Technology into its facilities.
    • OMNIQ Corp. (NASDAQ:OMQS) climbed 20.8% to $5.47.
    • Vapotherm, Inc. (NYSE:VAPO) rose 19.4% to $0.5001.
    • Helen of Troy Limited (NASDAQ:HELE) shares gained 19.1% to $97.39 after the company announced better-than-expected Q4 results.
    • Nuburu, Inc. (NYSE:BURU) gained 19% to $1.13.
    • Bel Fuse Inc. (NASDAQ:BELFB) rose 18.3% to $36.25 following better-than-expected quarterly results.
    • Immuron Limited (NASDAQ:IMRN) gained 16.4% to $2.23.
    • CXApp Inc. (NASDAQ:CXAI) climbed 16% to $10.74.
    • Mainz Biomed N.V. (NASDAQ:MYNZ) gained 15.6% to $3.92.
    • Accuray Incorporated (NASDAQ:ARAY) jumped 15% to $3.1050 after the company reported better-than-expected Q3 EPS and sales results.
    • LianBio (NASDAQ:LIAN) rose 14.7% to $2.26. LianBio announced topline results from the Phase 3 EXPLORER-CN trial investigating mavacamten for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
    • Meta Platforms, Inc. (NASDAQ:META) climbed 14.3% to $239.64 as the company reported better-than-expected Q1 results and also announced an increase in active users.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) gained 14.1% to $2.13 after Nexcella, an Immix Biopharma subsidiary, disclosed positive 58-patient NXC-201 clinical data.
    • GRI Bio, Inc. (NASDAQ:GRI) gained 14.1% to $6.79.
    • Goosehead Insurance, Inc (NASDAQ:GSHD) jumped 13.8% to $61.15 following upbeat quarterly results.
    • Overstock.com, Inc. (NASDAQ:OSTK) rose 13.7% to $20.54 following strong quarterly results.
    • Ardagh Metal Packaging S.A. (NYSE:AMBP) gained 13.5% to $3.93 following Q1 results.
    • Materialise NV (NASDAQ:MTLS) gained 13% to $8.80 as the company posted upbeat Q1 results and named Koen Berges as CFO.
    • Cimpress plc (NASDAQ:CMPR) jumped 12.4% to $48.72 following strong quarterly sales.
    • Hasbro, Inc. (NASDAQ:HAS) gained 10.8% to $57.00 after the company reported better-than-expected Q1 sales results and reiterated FY23 adjusted EPS guidance above the estimate.
    • Mangoceuticals, Inc (NASDAQ:MGRX) surged 10.7% to $1.3418 after dropping around 33% on Wednesday. Mangoceuticals recently commenced online sales campaign with DojoLabs Group.
    • Getaround, Inc. (NYSE:GETR) climbed 9.9% to $0.4999. Getaround received continued listing standard notice from NYSE related to delayed filing of Form 10-K.
    • Kaiser Aluminum Corporation (NASDAQ:KALU) gained 9.7% to $63.82 following Q1 results.
    • OpGen, Inc. (NASDAQ:OPGN) gained 6% to $0.88 after the company said its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development collaboration agreement with FIND.

    Losers

    • Baudax Bio, Inc. (NASDAQ:BXRX) fell 52.5% to $0.8406 after the company reported the pricing of $4 million public offering.
    • Impinj, Inc. (NASDAQ:PI) dropped 35.2% to $87.71 after the company reported mixed Q1 results and issued weak guidance.
    • 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares fell 31.1% to $14.18. 4DMT presented interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial in patients with wet AMD at ARVO 2023.
    • Aspen Technology, Inc. (NASDAQ:AZPN) fell 25% to $173.76 after the company posted downbeat Q3 results and issued weak FY23 forecast.
    • Mobileye Global Inc. (NASDAQ:MBLY) dropped 22% to $33.58 after the company lowered FY23 revenue guidance below estimates.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) fell 20.6% to $0.1206. Crown Electrokinetics recently issued a letter to shareholders.
    • Satixfy Communications Ltd. (NYSE:SATX) dropped 19.8% to $0.8101.
    • PROCEPT BioRobotics Corporation (NASDAQ:PRCT) fell 19.2% to $28.89 following wider-than-expected Q1 loss.
    • Crocs, Inc. (NASDAQ:CROX) fell 18.5% to $120.35 after the company reported Q1 earnings results and after the company issued Q2 guidance.
    • ETAO International Co., Ltd. (NASDAQ:ETAO) shares dropped 18.3% to $0.96 after gaining around 57% on Wednesday.
    • NETGEAR, Inc. (NASDAQ:NTGR) dipped 18.1% to $13.77 following weak quarterly results.
    • Ideanomics, Inc. (NASDAQ:IDEX) fell 17.2% to $0.0227 after dropping around 22% on Wednesday.
    • Kuke Music Holding Limited (NYSE:KUKE) dropped 16.9% to $0.60.
    • Wolfspeed, Inc. (NYSE:WOLF) fell 16.2% to $48.11 after the company issued weak Q4 guidance.
    • Avinger, Inc. (NASDAQ:AVGR) fell 15.5% to $0.54.
    • MaxLinear, Inc. (NYSE:MXL) dipped 15.5% to $24.78 after the company issued weak Q2 guidance.
    • IN8bio, Inc. (NASDAQ:INAB) fell 13.3% to $1.6902. IN8bio announced oral presentation of new INB-200 Phase 1 data in glioblastoma to be presented at 2023 ASCO Annual Meeting.
    • H&E Equipment Services, Inc. (NASDAQ:HEES) declined 12% to $36.36 following Q1 results.
    • Align Technology, Inc. (NASDAQ:ALGN) fell 11.7% to $312.85 after the company reported Q1 financial results and issued guidance.
    • Opera Limited (NASDAQ:OPRA) dropped 11.6% to $10.04 following Q1 results.
    • Sonic Automotive, Inc. (NYSE:SAH) gained 11.3% to $46.28 following weak quarterly results.
    • American Rebel Holdings, Inc. (NASDAQ:AREB) shares fell 11% to $0.1371 after gaining around 14% on Wednesday.
    • National Energy Services Reunited Corp. (NASDAQ:NESR) dipped 11% to $2.94 after the company announced it was not able to file its Annual Report on Form 20-F for its fiscal year ended December 31, 2021 with the SEC.
    • Clearmind Medicine Inc. (NASDAQ:CMND) fell 10.5% to $0.62. CONMED said it sees FY23 EPS of $3.30 to $3.50 and revenue of $1.205 billion to $1.250 billion.
    • Morningstar, Inc. (NASDAQ:MORN) dropped 9.3% to $172.95 following Q1 results.
    • AbbVie Inc. (NYSE:ABBV) dropped 8.5% to $147.95 after the company reported Q1 financial results and issued FY23 guidance.
    • Mobiquity Technologies, Inc. (NASDAQ:MOBQ) fell 8.4% to $0.1718 after jumping 22% on Wednesday. Mobility Technologies recently announced its AI-powered ad targeting technology.
    • STMicroelectronics N.V. (NYSE:STM) shares dropped 8.4% to $42.37 after reporting Q1 results.

    Now Read This: Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ALGN
    $AMBP
    $ARAY

    CompanyDatePrice TargetRatingAnalyst
    Hasbro Inc.
    $HAS
    3/11/2026$98.00Equal Weight
    Wells Fargo
    Crocs Inc.
    $CROX
    3/10/2026Neutral
    BTIG Research
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    Meta Platforms Inc.
    $META
    3/5/2026Buy → Neutral
    Arete
    Meta Platforms Inc.
    $META
    3/5/2026Hold → Buy
    Erste Group
    Sonic Automotive Inc.
    $SAH
    3/4/2026Neutral
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO and Corp Secretary Sibley Tarrant L. covered exercise/tax liability with 3,086 shares, decreasing direct ownership by 5% to 58,043 units (SEC Form 4)

    4 - HASBRO, INC. (0000046080) (Issuer)

    3/10/26 9:52:22 PM ET
    $HAS
    Recreational Games/Products/Toys
    Consumer Discretionary

    SEC Form 4 filed by Hasbro Inc.

    4 - HASBRO, INC. (0000046080) (Issuer)

    3/10/26 9:45:23 PM ET
    $HAS
    Recreational Games/Products/Toys
    Consumer Discretionary

    Chief Executive Officer Cocks Christian P covered exercise/tax liability with 16,621 shares, decreasing direct ownership by 5% to 287,082 units (SEC Form 4)

    4 - HASBRO, INC. (0000046080) (Issuer)

    3/10/26 9:40:41 PM ET
    $HAS
    Recreational Games/Products/Toys
    Consumer Discretionary

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

    Vancouver, Canada, March 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the continuation of participant enrollment for the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The recruitment follows the positive topline results recently reported from the secon

    3/11/26 9:07:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U POWER's Electric Heavy Trucks Pass Comprehensive Operational Testing and Full-Stack Integration of Battery-Swapping System; 1,000 Units Set for Thailand Rollout

    BANGKOK, March 11, 2026 /PRNewswire/ -- U Power Limited (NASDAQ:UCAR) ("U Power" or the "Company"), a provider of AI-integrated solutions for next-generation energy grids and intelligent transportation systems, today announced that it has successfully completed comprehensive operational testing and full-stack integration of the battery-swapping system of heavy-duty truck prototype vehicles designed to be deployed in Thailand. This milestone marks a key step forward in U Power's collaboration with Whale Logistics (Thailand) Co., Ltd. ("Whale Logistics"), a strategic partner, to d

    3/11/26 9:00:00 AM ET
    $UCAR
    Auto Parts:O.E.M.
    Consumer Discretionary

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Hasbro with a new price target

    Wells Fargo initiated coverage of Hasbro with a rating of Equal Weight and set a new price target of $98.00

    3/11/26 8:37:56 AM ET
    $HAS
    Recreational Games/Products/Toys
    Consumer Discretionary

    BTIG Research initiated coverage on Crocs

    BTIG Research initiated coverage of Crocs with a rating of Neutral

    3/10/26 8:40:26 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Holt Michael bought $186,590 worth of shares (1,000 units at $186.59), increasing direct ownership by 12% to 9,480 units (SEC Form 4)

    4 - Morningstar, Inc. (0001289419) (Issuer)

    3/4/26 4:54:30 PM ET
    $MORN
    Investment Managers
    Finance

    Director Goldberg Louis bought $250,039 worth of shares (5,575 units at $44.85) (SEC Form 4)

    4 - Goosehead Insurance, Inc. (0001726978) (Issuer)

    2/25/26 7:28:44 PM ET
    $GSHD
    Specialty Insurers
    Finance

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    SEC Filings

    View All

    Mainz Biomed N.V. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MAINZ BIOMED N.V. (0001874252) (Filer)

    3/11/26 7:35:06 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    3/10/26 9:29:59 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-1 filed by U Power Limited

    F-1 - U Power Ltd (0001939780) (Filer)

    3/9/26 9:38:28 PM ET
    $UCAR
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Nishant Sinha Joins Atomera as Head of Marketing to Drive Strategy and Growth in Advanced Semiconductor Materials

    Atomera Incorporated (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today announced the appointment of Nishant Sinha as its new Head of Marketing. The addition reflects the company's continued focus on accelerating growth amid the AI fueled semiconductor ecosystem. Sinha brings over 25 years of experience in the semiconductor industry spanning strategy, business development and growth leadership. As VP of Marketing, reporting to the CEO, Sinha will lead Atomera's marketing, strategy and customer development focusing on expanding adoption of the company's core Mears Silicon Technology™ (MST®). His deep expertise across semiconductor process, integration, value c

    2/26/26 4:05:00 PM ET
    $ATOM
    Semiconductors
    Technology

    Wolfspeed Strengthens Global Sales Leadership with Addition of Semiconductor Leader, Stefan Steyerl, as VP of Sales, EMEA

    Wolfspeed, Inc. (NYSE:WOLF), a global leader in silicon carbide technology and manufacturing, today announced the appointment of Stefan Steyerl as vice president of sales, EMEA. Effective March 1, 2026, Steyerl will develop and execute Wolfspeed's regional sales strategy, driving adoption of silicon carbide solutions across automotive, industrial, and energy markets as Wolfspeed accelerates the adoption of silicon carbide technology to expand its market footprint and deliver revenue growth across the region. Steyerl brings more than 25 years of experience in the semiconductor industry, with a proven track record of building high-performance teams and achieving revenue growth across global

    2/17/26 8:00:00 AM ET
    $WOLF
    Semiconductors
    Technology

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Financials

    Live finance-specific insights

    View All

    Morningstar Unveils Agenda for 2026 Morningstar Investment Conference

    The 38th annual conference aims to deliver clarity, perspective, and actionable insights so advisors and investors have nothing standing in the way of their long-term goals Morningstar, Inc. (NASDAQ:MORN), a leading provider of independent investment insights, today announced the agenda for its 38th annual Morningstar Investment Conference, taking place June 17-18, 2026, at Chicago's iconic Navy Pier. Grounded in Morningstar's independent perspective and brought to life by leading voices in the industry, the conference seeks to tackle today's most pressing investment challenges with clear, actionable strategies and timely insights. "This year's agenda is built around the obstacles advis

    3/10/26 8:00:00 AM ET
    $MORN
    Investment Managers
    Finance

    Bel Fuse Inc. Announces Acquisition of dataMate, an advanced ethernet and broadband business, from Methode Electronics Inc

    WEST ORANGE, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Bel Fuse Inc.® (NASDAQ:BELFA) ("Bel" or "the Company"), a leading global manufacturer of products that power, protect and connect electronic circuits, is pleased to announce the acquisition of dataMate®, a leading solutions provider of advanced ethernet and broadband technologies, from Methode Electronics Inc.® Bel acquired dataMate for $16 million, including $1 million of deferred consideration. With annual sales of approximately $18 million and operating margins in line with Bel's corporate averages, the dataMate acquisition is expected to be immediately accretive to Bel's financials. This transaction expands Bel's portfolio and posi

    3/5/26 4:15:00 PM ET
    $BELFA
    $BELFB

    STMicroelectronics to host investor calls on Cloud AI and Intelligent Sensing Enabling Physical AI

    STMicroelectronics to host investor calls on Cloud AI and Intelligent Sensing Enabling Physical AI Geneva, March 2, 2026 - STMicroelectronics N.V. ("ST") (NYSE:STM) will host two webcasts for investors and analysts in March 2026. "ST for Cloud AI", hosted by Remi El-Ouazzane, President of ST's MDRF Group. Conference call & webcast on March 9, 2026, at 3.30pm CET / 10.30am ET. "ST Intelligent Sensing Enabling the Physical AI", hosted by Marco Cassis, President of ST's APMS Group. Conference call & webcast on March 16, 2026, at 3.30pm CET / 10.30am ET. Presentations will be followed by a Q&A session. A live webcast (listen-only mode) of the conference will be accessible at ST's website,

    3/2/26 2:15:00 AM ET
    $STM
    Semiconductors
    Technology

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $ALGN
    $AMBP
    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Morningstar Inc.

    SC 13G - Morningstar, Inc. (0001289419) (Subject)

    12/10/24 4:15:15 PM ET
    $MORN
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Wolfspeed Inc.

    SC 13G/A - WOLFSPEED, INC. (0000895419) (Subject)

    12/6/24 11:56:48 AM ET
    $WOLF
    Semiconductors
    Technology

    Amendment: SEC Form SC 13D/A filed by Opera Limited

    SC 13D/A - Opera Ltd (0001737450) (Subject)

    12/6/24 6:15:42 AM ET
    $OPRA
    Computer Software: Prepackaged Software
    Technology